Adicet Bio, Inc.
ACETNasdaq
$8.12
↓ -1.2%Jul 17 close · end-of-day
Price
1Y↓ -34.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$87.2M
Enterprise Value
$51.0M
P/E
—
P/S
—
P/B
0.6
EV/EBITDA
—
PEG
—
FCF Yield
-105.0%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$108.8M
Free Cash Flow (TTM)
-$91.6M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-77.7%
ROIC
-86.6%
Debt / Equity
—
Net Cash
$36.2M
Return 1Y
-35.8%
Company profile
Adicet Bio, Inc. discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. Lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma.
- CEO
- Chen Schor
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 90
- Headquarters
- Massachusetts
- Website
- adicetbio.com
Management & directors
- Aftab BlakeChief Scientific Officer
- Harvey Brian NicholasChief Financial Officer
- Healey DonChief Technology Officer
- Schor ChenPresident & CEO
Roles derived from SEC Form 4 filings.
Earnings
ACET Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$1.88↓ -62.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$39.2M | -$61.4M | -$72.6M | -$152.0M | -$127.6M | -$122.1M |
| Net income | -$36.7M | -$62.0M | -$69.8M | -$142.7M | -$117.1M | -$116.8M |
| Diluted EPS | — | -$2.00 | -$1.70 | -$3.31 | -$21.33 | -$16.95 |
| Operating cash flow | -$41.6M | -$51.1M | -$44.8M | -$93.7M | -$92.4M | -$95.2M |
| Free cash flow | -$42.5M | -$64.1M | -$61.5M | -$98.2M | -$93.5M | -$97.0M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$32.8M | -$33.2M | -$30.7M | -$29.9M | -$32.4M | -$28.0M | -$31.9M | -$21.6M |
| Net income | -$29.9M | -$30.5M | -$28.7M | -$28.2M | -$31.2M | -$26.9M | -$30.5M | -$20.2M |
| Diluted EPS | -$0.33 | -$0.34 | -$20.31 | -$4.96 | -$0.34 | -$0.29 | -$11.36 | -$1.88 |
| Operating cash flow | -$23.4M | -$22.0M | -$24.1M | -$25.4M | -$26.6M | -$22.3M | -$20.9M | -$21.5M |
| Free cash flow | -$23.7M | -$22.4M | -$24.3M | -$26.9M | -$26.7M | -$22.5M | -$20.9M | -$21.5M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 1, 2026
Jun 29, 2026
Jun 4, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-04-27 | RA CAPITAL MANAGEMENT, LLC | J | 250,000 | — | — | filing |
| 2026-04-08 | ORBIMED ADVISORS LLC | Sale | 40,416 | $6.52 | $263,512.32 | filing |
| 2026-04-08 | ORBIMED ADVISORS LLC | Sale | 32,523 | $6.29 | $204,569.67 | filing |
| 2026-04-07 | ORBIMED ADVISORS LLC | Sale | 29,319 | $6.53 | $191,453.07 | filing |
| 2026-04-07 | ORBIMED ADVISORS LLC | Sale | 2,400 | $6.38 | $15,312.00 | filing |
| 2026-02-20 | RA CAPITAL MANAGEMENT, LLC | Buy | 74,751 | $7.27 | $543,439.77 | filing |
| 2026-02-19 | RA CAPITAL MANAGEMENT, LLC | Buy | 74,268 | $7.21 | $535,472.28 | filing |
| 2026-02-18 | RA CAPITAL MANAGEMENT, LLC | Buy | 74,577 | $7.04 | $525,022.08 | filing |
| 2026-01-24 | Schor Chen· President & CEO | Tax withholding | 1,755 | $8.44 | $14,812.20 | filing |
| 2026-01-24 | Harvey Brian Nicholas· Chief Financial Officer | Tax withholding | 546 | $8.44 | $4,608.24 | filing |
| 2026-01-24 | Aftab Blake· Chief Scientific Officer | Tax withholding | 535 | $8.44 | $4,515.40 | filing |
| 2026-01-24 | Healey Don· Chief Technology Officer | Tax withholding | 535 | $8.44 | $4,515.40 | filing |
| 2025-10-08 | ORBIMED ADVISORS LLC | Buy | 3,500,000 | $1.00 | $3.5M | filing |
| 2025-10-08 | ORBIMED ADVISORS LLC | Buy | 1,500,000 | $1.00 | $1.5M | filing |
Latest 14 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.